In The News
2018 Cleveland & Akron Race for the Cure Dates Announced
|25th Annual Cleveland Race for the Cure
Saturday, August 18th, 2018
6500 Cleveland Memorial Shoreway
Cleveland, OH 44102
|6th Annual Akron Race for the Cure
Saturday, October 13th, 2018
Canal Park Stadium
300 S. Main Street
Akron, OH 44308
This is a big year for
annual Cleveland Race for the Cure: it’s our 25th Anniversary! We
are excited to announce that this year’s race will be held on August 18th,
2018 at a brand new location - Edgewater Park.
option of running or walking the 5k or 1 mile route will be available and will take participants through different parts of the 147 acre lakefront
reservation. Registration opens April 1st. Stay tuned to www.ClevelandRacefortheCure.com for more details!
Annual Akron Race for the Cure event will take place at Canal Park on Saturday,
October 13th. Registration for the Akron Race also opens on April 1st. Stay tuned
to www.AkronRacefortheCure.com for more details!
Registration Now Open for the 2018 Metastatic Breast Cancer Conference
The Metastatic Breast Cancer Conference is designed to educate
metastatic patients, breast cancer survivors, caregivers, and the
general public on the ABCs of metastatic breast cancer. The first
conference of it’s kind in Northeast Ohio, this event offers information
on everything from the biology and causes of metastatic tumors to how
to get involved in clinical trials, complementary therapies, and
everything in between.
The Metastatic Conference features keynote
presentations from Mary McGillicuddy of the Metastatic Breast Cancer
Project and Komen Research Scholar Dr. Danny Welch of the University of
Kansas, a panel of prestigious local oncologists, an interactive
complementary therapy fair, vendor fair, and much more.
Click here to register, download a full conference agenda, and learn more about the 2018 Metastatic Breast Cancer Conference.
This event costs $10 to attend. For those who cannot afford this
fee, please contact Gina at email@example.com or (216) 292-2873
to receive a discount code. The Metastatic Breast Cancer Conference is presented by MetroHealth and Ganley Auto Group.
Now Accepting Nominations for the Jones-Hendryx Forever Fighter Award
The Jones-Hendryx Forever Fighter Award
honors the memory of Carol Jones and Jennifer Hendryx, who both passed
away from metastatic breast cancer in late 2017. Their optimism and
determination throughout their fight with metastatic disease was an
inspiration to others and helped Komen Northeast Ohio renew our
commitment to raising awareness of Stage 4 breast cancer.
Jones-Hendryx Forever Fighter Award recognizes an individual,
corporation, or organization who champions the Komen promise with the
courage and limitless boundaries of Carol and Jennifer. The nominee goes
beyond the scope of activist to inspire others to help in the fight
against metastatic disease.
Nominations for the Jones-Hendryx Forever Fighter Award nominations are due by February 5th, 2018. Please click here to download the official nomination form.
Save the Date - 2018 Breast Cancer Symposium
Susan G. Komen Northeast Ohio will host the 14th Annual Breast Cancer Survivor Symposium on Saturday, October 20th, 2018 at the DoubleTree Hotel in Independence. This annual event strives to celebrate survivorship and provide education and information on issues affecting those who have gone through a breast cancer diagnosis. Visit www.komenneohio.org for more details.
The Cleveland Clinic has
supported Susan G. Komen Northeast Ohio for many years. Providing more than $150,000 to Komen NEO through various event sponsorships, Race for the Cure teams, and in-kind services, the Cleveland Clinic has become an integral partner in the local fight against breast cancer. We cannot thank them - and their staff - enough for their support of our affiliate and the community!
Cleveland Clinic is ranked
No. 1 in Ohio and No. 7 in the nation for cancer care by U.S.
News & World Report. The
Comprehensive Breast Cancer Program is one of the largest and most specialized
in the nation. As part of the Case Comprehensive Cancer, they are one of only
41 comprehensive cancer centers in the nation designated by the National Cancer
They are a national leader
in intraoperative radiation therapy, novel targeted therapies and adjuvant
therapies for breast cancer, and also in fertility preservation for cancer
patients. They also participate in important clinical trials of brand new
therapies and their patients have access to these trials for every stage of
breast cancer. Their cancer specialists are pursuing many promising avenues of
research — including the development of a breast cancer vaccine — to bring hope
to future patients as well.
Community & Partner Events
The Hard Rock Rocksino of Northfield Park will host a
charity concert to benefit Komen Northeast Ohio on Wednesday, March 28th
at 7:00pm. The concert features local bands Witness Protection, Verve Daddy, and HereAfter. Doors to Club Velvet open at 6:00pm for VIPs and 6:30pm for general admission. This event will include auctions, raffles, cash bar, and more!
Tickets will be available on February 5th at www.komenneohio.org. VIP tickets include early entry to the event, 2 complimentary drink tickets, complimentary champagne, and a swag bag; VIP tickets cost $75 each. General admission tickets cost $25. Don’t miss out on seeing some amazing local bands to support the women of Northeast Ohio.
||Susan G. Komen Northeast Ohio is proud to partner with Smart Business
for their 2018 Smart Women Breakfast. The event will take place on April 26th, 2018 from 7:30am-10:30am at La Centre Conference & Banquet Facility in Westlake.
This event combines a live event and content — digital and print — to address today’s issues facing women in the workplace. At this event Smart Business will also recognize the achievements of leading businesswomen, inspiring male advocates and effective women’s programs during the Smart Women Awards. For more information on the event or to register to attend, please click here.
Did You Know?
Pertuzamab (Perjeta), a targetd therapy drug, was recently FDA approved for the treatment of breast cancer in the adjuvant setting (meaning in addition to surgery and radiation therapy). A randomized clinical trial of women with HER-2 positive early breast cancer showed pertuzumab in combination with trastuzumab and chemotherapy after surgery reduced the risk of breast cancer recurrency by about 20 percent. Click here to learn more.
University Hospitals Seidman Cancer Center
Enrolling Patients for National Research Screening Study
Donna Plecha, MD, Director of
Breast Imaging, is the site principal investigator for an exciting ECOG/ACRIN
study evaluating a low-cost abbreviated MRI protocol (less than 10 minutes). This quick MRI will be a supplemental screening method to digital breast tomosynthesis in women with dense breasts. Specifically, the trial is measuring the detection of invasive cancers. Patients will undergo tomosynthesis and abbreviated MRI on the same day. The tomosynthesis is a clinical standard of care covered by insurance, and the abbreviated MRI will be covered by the study. The patient will have a tomosynthesis and abbreviated MRI this year and next year (two rounds) and then will be followed for three years.
The study is being conducted at UH Westlake Health Center and at UH Main Campus. This is an advanced imaging, high-impact, phase II trial with the potential to change the standard of care and improve clinical outcomes for breast cancer patients.
The sensitivity of breast MRI is substanially higher than
mammography leading to earlier detection, earlier treatment and potentially
reduced mortality. MRI may also detect biologically significant tumors at a
smaller size and earlier stage, which may lead to an overall reduction in
surgical and adjuvant therapies and their associated morbidities. Patients are
currently being enrolled in this advanced imaging, high-impact study.
Questions, email firstname.lastname@example.org.
For more information click here.